health · HHS-NIH11

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

National Institutes of Health · PAR-25-024

504 days left

Deadline

January 7, 2028

GRANTQUICK SUMMARYPlain-English Overview

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional). National Institutes of Health. The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical... Funding amounts not specified.

Who Should Apply

City/township governments, Other eligible entities, Public And Indian Housing Authorities, Nonprofits (501c3), Nonprofits (non-501c3) (+10 more)

Who Should NOT Apply

Organizations not matching the eligible applicant types listed above

Key Requirements (Plain English)

•Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Is...
•Deadline: 2028-01-07

💡 GrantQuick Tip

Focus your proposal on clear outcomes, alignment with agency priorities, and demonstrate organizational capacity.

Competitiveness: Moderate to high — federal grants are always competitive

What This Grant Funds

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Attachments

PDF

PAR-25-024 Full Announcement Text

PAR-25-024-Full-Announcement.html

Who Can Apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Eligible Applicant Types

City/Township GovernmentsOther (see NOFO for details)Public And Indian Housing Authorities501(c)(3) NonprofitsNonprofits without 501(c)(3)Federally Recognized Tribal GovernmentsIndependent School DistrictsSmall BusinessesSpecial District GovernmentsFor-Profit OrganizationsPublic Colleges & UniversitiesOther Tribal OrganizationsState GovernmentsCounty GovernmentsPrivate Colleges & Universities

Funding Details

Cost Sharing Required?: No
Funding Instrument: grant

Key Dates

Posted: October 28, 2024

Application Deadline: January 7, 2028 (504 days remaining)

Agency Contact

NIH Grants Information grantsinfo@nih.gov

grantsinfo@nih.gov

Ready to apply?

View the full NOFO and submit your application on Grants.gov

View on Grants.gov